A081105- Randomized Study Of Erlotinib Vs Observation In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (Nscls)
Posted Date: May 15, 2019
- Investigator: Christopher Lemmon
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
The purpose of this study is To assess whether adjuvant therapy with erlotinib will result in improved overall survival over observation for patients with completely resected stage IB-IIIA EGFR mutant NSCLC following complete resection and standard post-operative therapy.
Criteria:
To Be Eligible: Previously Registered To A151216, Must Have Early Stage Nsclc, Age 18 Or Older, Nonpregnant/Nonlactating
Keywords:
Lung Cancer, Nsclc, Cancer, Lung
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com